Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
Healthcare
$3.28 +0.00%
+$0.00 today
- Market cap
- $571.17M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
52W Low $0.91High $3.22
Volume 0.23M
Average 0.16M
Income Statement
Follow revenue through to earnings.
Revenue
$42,000.00
FY 2025 · Annual
-76.8% YoYOperating Income
-$11.53M
FY 2025 · Annual
Net Income
-$11.44M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 571K | 134K | 0 | 181K | 42K |
| Cost of Revenue | 373K | 165K | 56K | 172K | 42K |
| Gross Profit | 198K | (31K) | (56K) | 9K | 0 |
| Gross Margin | 34.7% | -23.1% | — | 5.0% | 0.0% |
| Research & Development | 6.77M | 5.78M | 4.45M | 4.5M | 6M |
| Selling, General & Admin | 5.69M | 7.25M | 4.43M | 5.1M | 5.53M |
| Operating Expenses | 12.42M | 13.04M | 8.88M | 9.59M | 11.53M |
| Depreciation & Amortization | 53K | 64K | 56K | 46K | 30K |
| EBITDA | (12.16M) | (12.87M) | (8.8M) | (9.48M) | (11.41M) |
| EBITDA Margin | -2130.3% | -9604.5% | — | -5238.1% | -27164.3% |
| Operating Income | (12.22M) | (13.07M) | (8.94M) | (9.59M) | (11.53M) |
| Operating Margin | -2139.6% | -9752.2% | — | -5295.6% | -27450.0% |
| Interest Income | 0 | 83K | 31K | 58K | 0 |
| Interest Expense | 29K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (29K) | 134K | 80K | 58K | 90K |
| Income Before Tax | (12.25M) | (12.93M) | (8.86M) | (9.53M) | (11.44M) |
| Pre-Tax Margin | -2144.7% | -9652.2% | — | -5263.5% | -27235.7% |
| Income Tax Expense | (59K) | 137K | 29K | 14K | 0 |
| Net Income | (12.19M) | (13.07M) | (8.89M) | (9.54M) | (11.44M) |
| Net Margin | -2134.3% | -9754.5% | — | -5271.3% | -27235.7% |
| EPS (Basic) | (0.47) | (0.45) | (0.31) | (0.25) | (0.25) |
| EPS (Diluted) | (0.47) | (0.45) | (0.31) | (0.25) | (0.25) |
| 26.13M | 28.81M | 29.01M | 37.65M | 46.19M | |
| 26.13M | 28.81M | 29.01M | 37.65M | 46.19M |
ENTX Earnings Waterfall · TTM
NASDAQ:ENTX · Revenue to Net Income
Key Ratios
EPS$-0.26
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-6.7
P/S Ratio0.0
Analysis
$0 of revenue converted into -$12.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.26, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 6, 2026 | |
| 8-K | Current report | Nov 6, 2026 | |
| SC 13G | SC 13G filing | Oct 30, 2026 | |
| 8-K | Current report | Oct 27, 2026 |
How much revenue does ENTX generate?
Entera Bio Ltd. (ENTX) reported $42,000.00 of revenue in fiscal 2025.
Is ENTX profitable?
Entera Bio Ltd. (ENTX) reported -$11.44M of net income, with a net margin of -27235.7%.
Continue the stock analysis
Jump to another research area for this company.